Mixor (Telmisartan, Amlodipine Besilate)

Telmisartan, one of the active ingredients in Mixor, selectively blocks angiotensin II type 1 (AT1) receptors. This inhibition prevents the vasoconstrictive and aldosterone‑secreting effects of angiotensin II, leading to reduced peripheral vascular resistance and lower blood pressure.

The appropriate dose of Mixor is determined by the prescribing healthcare professional based on the individual’s blood‑pressure goals, renal function, and other clinical factors. Patients should follow the exact dosage instructions provided by their prescriber and not adjust the dose on their own.

Safety of Mixor in pregnancy or while breastfeeding has not been fully established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To order Mixor, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mixor offers a fixed‑dose combination of an angiotensin II receptor blocker and a calcium‑channel blocker, which can simplify therapy compared with taking two separate tablets. This combination may improve adherence and provide additive blood‑pressure reduction, whereas monotherapy with either class alone may be less effective in some patients.

Mixor tablets should be stored at room temperature, below 25 °C, in the original packaging. Keep them away from moisture, direct sunlight and heat sources to maintain product stability throughout its shelf life.

Mixor is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. The tablet should be swallowed whole with a full glass of water and not chewed or crushed unless specifically instructed.

Serious risks include angioedema, severe hypotension, liver enzyme elevations, and rare but life‑threatening allergic reactions such as Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience swelling of the face or throat, persistent dizziness, jaundice, or severe skin rash.

Mixor should be avoided in individuals with known hypersensitivity to telmisartan, amlodipine, or any excipients in the tablet. It is also contraindicated in patients with severe hepatic impairment, and caution is advised in those with renal dysfunction, pregnancy, or concurrent use of certain interacting medications.